All entries for: BioNTech

“BioNTech will close its Berlin-based subsidiary JPT Peptide Technologies by year’s end, cutting about 140 jobs as it focuses on its late-stage oncology pipeline, per a quarterly report. JPT is a contract manufacturer specializing in peptide-based products and services.

The German company is also closing manufacturing sites in Idar-Oberstein and Marburg, along with CureVac’s facilities in Germany and abroad, by the end of next year, plus a Singapore site by Q1 2027. Those closures affect roughly 1,860 jobs.”

BioNTech has outlined plans to close multiple manufacturing facilities by the end of next year, affecting about 1,860 jobs.

The German biotech intends to shutter three facilities in its home country. BioNTech’s Idar-Oberstein, Marburg and Tübingen sites are scheduled for closure by the end of next year. As previously disclosed, the biotech is also exiting a manufacturing facility in Singapore. BioNTech expects to conclude operations at the Singapore facility by the first quarter of next year.

Efforts to consolidate the manufacturing network are focused on sites where capacity will become idle or underused within 24 months, BioNTech CFO Ramón Zapata said on the company’s first-quarter earnings call on May 5. BioNTech is exploring divestment options, including partial and total sales of the plants.

BioNTech is closing a Singapore production plant less than four years after buying the site from Novartis to supply mRNA vaccines and therapies in the Asia-Pacific region. Last week, the Germany-based company told The Straits Times that the planned Singapore site will close by February 2027. BioNTech employs 85 people at the plant.

The company, which framed the shuttering as part of efforts to align capacity with its pipeline and long-term strategic direction, also had layoffs last year. BioNTech let go of 63 employees in August in connection with closing its cell therapy facility in Gaithersburg, Maryland. Around the same time, news broke that it would lay off 90 employees across its U.S. footprint, including 32 people at its Gaithersburg office and lab space, effective in September 2025, and 58 in Cambridge, Massachusetts.